Dianthus Therapeutics Ends Third Quarter With $1.2 Billion in Cash

Dianthus Therapeutics, a clinical-stage biotechnology company based in New York and Waltham, Massachusetts, said on November 4, 2026 that it held roughly $1.2 billion in cash as of September 30, 2026, enough to fund planned operations into 2030, as it released results for its third quarter.

The company, which trades on the Nasdaq under DNTH, is developing claseprubart, an experimental antibody aimed at the classical complement pathway and designed to be injected under the skin by patients themselves every two or four weeks. Dianthus said a Phase 2 study of the drug in multifocal motor neuropathy should produce initial data in December 2026, with a Phase 3 study in that disease planned for 2027.

Two later-stage trials are also under way. Dianthus expects initial data from the first portion of its Phase 3 CIDP study by the end of 2027 and from the second portion by the end of 2028, while its Phase 3 trial in generalized myasthenia gravis is scheduled to read out in the second half of 2028. The U.S. Food and Drug Administration granted claseprubart orphan drug status in myasthenia gravis in May 2026.

Two other candidates, DNTH212 and DNTH312, remain in early development, the company said. None of the three has regulatory approval anywhere, according to the release distributed by GlobeNewswire.

This story was first reported by GlobeNewswire.